Skip Navigation



Annals of Oncology Advance Access published online on August 5, 2008
Annals of Oncology, doi:10.1093/annonc/mdn551
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/1/121    most recent
mdn551v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kim, B.-S.
Right arrow Articles by Kim, N. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, B.-S.
Right arrow Articles by Kim, N. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

B.-S. Kim1,4, D.-W. Kim2,4, S.-A. Im2,4, C. W. Kim3, T.-Y. Kim2,4, S.-S. Yoon2,4, D. S. Heo2,4,*, Y.-J. Bang2,4, S. Park2,4, B. K. Kim2,4 and N. K. Kim5

1 Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul
2 Department of Internal Medicine, Seoul
3 Department of Pathology, Seoul National University Hospital, Seoul
4 Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul
5 Department of Internal Medicine, Center for Gastric Cancer, National Cancer Center Hospital, Goyang-si, Gyeonggi-do, South Korea

* Correspondence to: Prof D. S. Heo, Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, South Korea. Tel: +82-2-2072-2857; Fax: +82-2-742-6689; E-mail: heo1013{at}snu.ac.kr

Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy.

Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks.

Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0–1 in thirteen, 2 in five, 3 in five, and 4–5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia.

Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.

NK/T-cell lymphoma, salvage chemotherapy, second-line chemotherapy

Received for publication January 6, 2008. Revision received June 30, 2008. Accepted for publication July 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al.
Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. J. Kim, S. Y. Oh, J. Y. Hong, M. H. Chang, D. H. Lee, J. Huh, Y. H. Ko, Y. C. Ahn, H.-J. Kim, C. Suh, et al.
When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
Ann. Onc., October 22, 2009; (2009) mdp412v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.